Ketamine infusion maximum dosage in acute liver failure
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
The textbook searches did not return a specific "maximum dosage" recommendation for ketamine infusion in the context of acute liver failure specifically. Here is a synthesis of what the authoritative medical literature states, combining textbook findings with established clinical knowledge:
Ketamine Infusion in Acute Liver Failure
The Core Problem: Ketamine Is Hepatically Metabolized
Ketamine undergoes extensive hepatic biotransformation (hepatic extraction ratio ~0.9) via CYP3A-mediated N-demethylation to norketamine, an active metabolite with ~20–30% of ketamine's potency. End products are renally excreted.
In acute liver failure (ALF), this creates two overlapping risks:
- Reduced clearance → accumulation of ketamine and norketamine → prolonged and intensified effects
- Direct hepatotoxicity — ketamine itself is associated with liver injury, particularly with high-dose or prolonged infusions (documented with two 100-hour S(+)-ketamine infusions in CRPS patients) — Miller's Anesthesia, 10e
Standard Dosing Reference Points (from textbooks)
| Indication | Dose |
|---|---|
| Analgesia (sub-dissociative) | 0.1–0.5 mg/kg IV |
| Procedural sedation | 1–2 mg/kg IV bolus |
| Status epilepticus (third-line) | Loading: 1.5 mg/kg IV over 3–5 min; may repeat 0.5 mg/kg; maintenance infusion 2–7.5 mg/kg/h — Rosen's Emergency Medicine |
| Acute pain infusion | 0.1–0.3 mg/kg IV over 10–15 min; can follow with 0.1 mg/kg/h infusion — Tintinalli's Emergency Medicine |
Dose Adjustment in Acute Liver Failure
No specific "maximum dose" for ketamine in ALF is established in the referenced major textbooks. However, the following principles apply:
Key pharmacokinetic considerations in ALF:
- The high hepatic extraction ratio means that even moderate hepatic dysfunction will significantly reduce first-pass/systemic clearance
- Norketamine accumulation can prolong sedation/analgesia unpredictably
- Ketamine's elimination half-life (~2 hours in normal liver) will be substantially prolonged
Clinical guidance (evidence-based principles):
- Start at the lower end of any dosing range and titrate to effect
- Reduce or extend dosing intervals for repeat boluses; avoid fixed-rate high-dose infusions
- Use the minimum effective dose — there is no validated "maximum" in ALF specifically, but the ceiling should be guided by effect, not weight-based targets
- Avoid prolonged high-dose infusions — hepatotoxicity risk compounds the underlying liver pathology
- ALF patients often have hemodynamic instability; ketamine's sympathomimetic effect may be useful in early shock but can be unpredictable with catecholamine depletion
Additional caution: Ketamine is not contraindicated in liver failure per standard references, unlike some agents (e.g., acetaminophen, NSAIDs). It remains useful for procedural sedation or refractory status epilepticus in ALF when alternatives are limited — but with close monitoring and dose reduction.
Practical Summary
| Parameter | Recommendation in ALF |
|---|---|
| Bolus dose | Reduce by ~25–50% from standard; titrate slowly |
| Infusion rate | Use lowest effective rate; avoid prolonged high-dose infusions |
| Monitoring | Titrate to clinical effect; watch for accumulation |
| Hepatotoxicity risk | Avoid repeat prolonged infusions; monitor LFTs |
| "Maximum dose" | Not defined for ALF specifically — individualize based on response and monitoring |
There is no universally validated specific maximum infusion dose of ketamine in acute liver failure in current major references. Dosing must be individualized, with downward adjustment, careful titration, and frequent reassessment given impaired clearance and compounded hepatotoxic risk.
— Miller's Anesthesia 10e | Morgan & Mikhail's Clinical Anesthesiology 7e | Rosen's Emergency Medicine | Tintinalli's Emergency Medicine
W3a a
Could you clarify what you mean by "W3a a"? It's not clear what you're asking. Are you referring to:
- A drug/classification (e.g., WHO class, a specific drug code)?
- A medical condition or staging system?
- Something else entirely?
Please provide more context so I can help accurately.
Mo
Asking for Preferences
This is a shared conversation. Sign in to Orris to start your own chat.